Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (121-130 of 238) with videos related to

Pageof 24
Sort By:
British Journal of Clinical Pharmacology|April 21, 2012
Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjectsLaurent B Nicolas, Andreas Krause, Marcelo M Gutierrez, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 25, 2013
Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulationMarcelo M Gutierrez, Laurent B Nicolas, Yves Donazzolo, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 9, 2024
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertensionJanneke M Brussee, Patricia N Sidharta, Jasper Dingemanse, et al.
Drugs in R&D|March 13, 2024
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male SubjectsIsabelle Zenklusen, Jasper Dingemanse, Christian Reh, et al.
Journal of Clinical Pharmacology|August 14, 2024
Multiple-dose pharmacokinetics of cenerimod and the effect of charcoal on its eliminationMarkus S Mueller, Pierre-Eric Juif, Hakim Charfi, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 30, 2022
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonistAndreas Krause, Dominik Lott, Janneke M Brussee, et al.
Sleep|December 11, 2020
Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apneaMarie-Laure Boof, Jasper Dingemanse, Katharina Lederer, et al.
Clinical Pharmacokinetics|April 10, 2013
Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjectsJacob Atsmon, Jasper Dingemanse, Dimitri Shaikevich, et al.
Drugs in R&D|November 12, 2013
Disposition and metabolism of setipiprant, a selective oral CRTH2 antagonist, in humansMatthias Hoch, Janine Wank, Ina Kluge, et al.
Journal of Clinical Pharmacology|August 9, 2018
Clinical Pharmacology of the Reversible and Potent P2Y<sub>12</sub> Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male SubjectsPierre-Eric Juif, Margaux Boehler, Michael Dobrow, et al.
Pageof 24

Showing results (121-130 of 238) with videos related to

Sort By:
Pageof 24
British Journal of Clinical Pharmacology|April 21, 2012
Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjectsLaurent B Nicolas, Andreas Krause, Marcelo M Gutierrez, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 25, 2013
Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulationMarcelo M Gutierrez, Laurent B Nicolas, Yves Donazzolo, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 9, 2024
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertensionJanneke M Brussee, Patricia N Sidharta, Jasper Dingemanse, et al.
Drugs in R&D|March 13, 2024
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male SubjectsIsabelle Zenklusen, Jasper Dingemanse, Christian Reh, et al.
Journal of Clinical Pharmacology|August 14, 2024
Multiple-dose pharmacokinetics of cenerimod and the effect of charcoal on its eliminationMarkus S Mueller, Pierre-Eric Juif, Hakim Charfi, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 30, 2022
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonistAndreas Krause, Dominik Lott, Janneke M Brussee, et al.
Sleep|December 11, 2020
Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apneaMarie-Laure Boof, Jasper Dingemanse, Katharina Lederer, et al.
Clinical Pharmacokinetics|April 10, 2013
Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjectsJacob Atsmon, Jasper Dingemanse, Dimitri Shaikevich, et al.
Drugs in R&D|November 12, 2013
Disposition and metabolism of setipiprant, a selective oral CRTH2 antagonist, in humansMatthias Hoch, Janine Wank, Ina Kluge, et al.
Journal of Clinical Pharmacology|August 9, 2018
Clinical Pharmacology of the Reversible and Potent P2Y<sub>12</sub> Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male SubjectsPierre-Eric Juif, Margaux Boehler, Michael Dobrow, et al.
Pageof 24